Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: equityanalyst who wrote (97)	2/2/2000 8:21:00 AM
From: equityanalyst	Read Replies (1) \| Respond to of 286

Richaaard et al -- This is BIG news. Reallllly BIG!!!!: -- WSJ(2/2): Biotech Leader Rathmann Is Quitting Icos For Hyseq -- By Ralph T. King Jr. Staff Reporter of The Wall Street Journal George B. Rathmann, a leader in the biotechnology industry, is stepping down as chairman of Icos Corp. to become chairman of Hyseq Inc., a move likely to fuel the already hot gene-research field. Icos reported Dr. Rathmann's departure, naming Paul N. Clark, the company's president and chief executive, to succeed him. Hyseq is expected to announce Dr. Rathmann's appointment today. Robert Weist, chairman of Hyseq since 1994, will become vice chairman. Dr. Rathmann, 72 years old, built Amgen Inc. into the nation's largest biotech company then, in 1991, took over at Icos, which has several promising therapies in late-stage tests, including an impotence drug that eventually may challenge Pfizer Inc.'s Viagra. In June, he relinquished his operating duties to Mr. Clark, 52, an Abbott Laboratories executive, and today's announcement "completes the management transition," Dr. Rathmann said. Dr. Rathmann said his move to Hyseq, a relatively low-profile company in Sunnyvale, Calif., reflects his enthusiasm for genomics, the discovery and analysis of genes, which is rapidly transforming drug research. He cited Hyseq's "enormous potential," both as a developer of genebased drugs and of new research tools. He has owned a minor stake in the company since 1993. Hyseq uses chip technology to gather information on genes that are particularly hard to find. Based on these discoveries, the company has two drug candidates, an anti-inflammatory and an anticlotting agent, in preclinical development. At 4 p.m. on the Nasdaq National Market, Hyseq was up 56.25 cents at $32.25 and Icos was down 43.75 cents at $34. With Dr. Rathmann on board, Hyseq could prove especially attractive to investors and talented scientists. Early in his career, he earned the nickname "Golden Throat" for his ability to raise money for early-stage research. At Icos, based in Bothell, Wash., he persuaded Microsoft Corp. Chairman Bill Gates to buy a sizable stake and join the board. "I enjoy defining an aggressive strategy and convincing people we are doing it," Dr. Rathmann said. (END) DOW JONES NEWS 02-02-00 12:07 AM- - 12 07 AM EST 02-02-00